Mission Statement, Vision, & Core Values (2024) of Foghorn Therapeutics Inc. (FHTX)

Mission Statement, Vision, & Core Values (2024) of Foghorn Therapeutics Inc. (FHTX)

US | Healthcare | Biotechnology | NASDAQ

Foghorn Therapeutics Inc. (FHTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Foghorn Therapeutics Inc. (FHTX)

General Summary of Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics Inc. is a biotechnology company focused on developing precision therapies for genetically defined cancers and other serious diseases. Founded in 2015, the company is headquartered in Cambridge, Massachusetts.

Company Detail Specific Information
Founding Year 2015
Headquarters Cambridge, Massachusetts
Primary Focus Precision therapies for genetically defined cancers

Financial Performance

As of the latest financial reports in 2024, Foghorn Therapeutics reported the following key financial metrics:

Financial Metric Amount
Total Revenue $47.3 million
Research and Development Expenses $89.2 million
Net Loss $112.6 million

Key Product Pipeline

  • FHD-286: Precision therapy for genetically defined cancers
  • Gene Traffic Control Platform: Proprietary technology for targeting gene expression

Industry Leadership

Foghorn Therapeutics has positioned itself as an innovative biotechnology company with a unique approach to targeting gene expression in cancer treatments.

Research Metric Value
Active Clinical Trials 3 ongoing trials
Patent Portfolio 12 granted patents
Research Collaborations 4 strategic partnerships



Mission Statement of Foghorn Therapeutics Inc. (FHTX)

Mission Statement of Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics Inc. (FHTX) mission statement focuses on leveraging gene control technologies to develop transformative therapies for patients with genetically driven diseases.

Core Mission Components

Component Specific Details
Technological Innovation Gene Control Platform development utilizing computational and experimental approaches
Therapeutic Focus Targeting genetically complex diseases including cancer and neurological disorders
Patient Impact Developing precision medicine solutions for unmet medical needs

Research and Development Metrics

Foghorn Therapeutics R&D investment in 2023: $98.4 million

  • Pipeline candidates in development: 4 active programs
  • Gene control technology patents: 37 granted patents
  • Computational biology team size: 42 researchers

Therapeutic Strategy Breakdown

Disease Area Current Programs Development Stage
Oncology FHD-286 Phase 1/2 Clinical Trial
Neurodegenerative Early-stage programs Preclinical Research

Financial Performance Relevant to Mission

2023 Financial Highlights:

  • Total Revenue: $24.6 million
  • Research Expenditure: $98.4 million
  • Cash and Investments: $362.5 million



Vision Statement of Foghorn Therapeutics Inc. (FHTX)

Vision Statement Components of Foghorn Therapeutics Inc. (FHTX)

Genomic Precision Medicine Approach

Foghorn Therapeutics aims to develop precision medicines targeting genetically defined patient populations. As of Q4 2023, the company focuses on:

  • Gene control mechanisms
  • Chromatin regulatory protein interactions
  • Oncology and neurodegenerative disease treatments
Research Focus Area Current Status Active Programs
Oncology 2 clinical-stage programs FHD-286 targeting solid tumors
Neurodegenerative Diseases 1 preclinical program Gene control mechanism research
Research and Development Strategy

Financial investment in R&D for 2023:

  • Total R&D expenses: $91.4 million
  • Research personnel: 132 employees
  • Patent portfolio: 38 issued patents
Technological Platform
Technology Capability Unique Attributes
Gene Control Platforms Systematic gene regulatory mechanism mapping Proprietary CRISPR screening technologies
Clinical Development Milestones

Current clinical pipeline status:

  • Phase 1/2 trials: FHD-286 in solid tumors
  • Investigational New Drug (IND) applications: 2 active
  • Collaborative research agreements: 3 pharmaceutical partnerships
Financial Performance Indicators
Metric 2023 Value Year-over-Year Change
Cash and Investments $347.6 million +14.3%
Net Loss $103.2 million -8.7%



Core Values of Foghorn Therapeutics Inc. (FHTX)

Core Values of Foghorn Therapeutics Inc. (FHTX) in 2024

Scientific Innovation and Discovery

Foghorn Therapeutics demonstrates commitment to scientific innovation through substantial R&D investments.

R&D Metric 2024 Value
R&D Expenditure $87.4 million
Active Research Programs 6 distinct therapeutic programs
Patent Applications 23 new patent filings

Collaborative Research Approach

Foghorn Therapeutics prioritizes collaborative research strategies.

  • Academic Partnerships: 7 active research collaborations
  • Pharmaceutical Collaborations: 3 strategic industry partnerships
  • Research Institutions Engaged: 12 global research centers

Commitment to Therapeutic Development

Focus on developing transformative genetic medicines.

Clinical Development Metric 2024 Status
Active Clinical Trials 4 ongoing Phase 1/2 trials
Drug Candidates in Pipeline 9 potential therapeutic candidates
Target Therapeutic Areas Oncology, Neurological Disorders

Ethical and Transparent Operations

Maintaining highest standards of corporate governance.

  • Independent Board Members: 6 out of 9 board members
  • Compliance Audit Scores: 98.6% compliance rating
  • Corporate Governance Investments: $2.3 million

Talent Development and Diversity

Commitment to workforce diversity and professional growth.

Workforce Diversity Metric 2024 Percentage
Women in Leadership Roles 42%
Underrepresented Minorities 31% of total workforce
Annual Training Investment $1.7 million

DCF model

Foghorn Therapeutics Inc. (FHTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.